• 

• The Aequitas Group
  • History
  • World Hospital Monitor
  • Capabilities Presentations
  • White Papers
    • Expanded Access Using Named Patient Programs
    • Expanded Access Programs May Facilitate Prelaunch Market Access in Canada
• Publications
• Clients
• Careers

Publications

Abstracts

• Atkinson M, Panaccione R, Plevy S, Kane S, Wolf D, Hass S, Panjabi S. Two new clinical assessment tools for Crohn’s disease patients: validation, sensitivity and specificity. Digestive Disease Week, April 2008, San Diego.
• Mcghan WF, Tundia N, Quadri H, Viswanathan S, Peterson AM. Evaluating an online calculator for analyzing incremental net benefit and the expected value of perfect information from patient level of data. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual International Meeting, May 19-23, 2007, Arlington, VA.
• Morlock RJ, Atkinson MJ, Pollock MR, Ho NJ, Mathies A. The economic burden of chronic lymphocytic leukemia in the United States. ISPOR 13th Annual International Meeting, May 3-7, 2008, Toronto, Canada.
• Morlock RJ, Atkinson MJ, Saville W, Pollock MR, Quadri H. The impact of Hodgkin’s lymphoma on health related quality of life. ISPOR 13th Annual International Meeting, May 3-7, 2008, Toronto, Canada.
• Petrozzino JP, Smith C, Atkinson MA. Rapid diagnostic testing for influenza: an evidence-based review and comparison with unaided clinical diagnosis. 30th Annual Meeting of the Society for Medical Decision Making, October 19-22, 2008, Philadelphia, PA.
• Restrepo MI, Murphy AL, Alejandro AA, Arroliga C, Atkinson MJ, Ho NJ, Quadri H, Kollef MH. Economic burden of ventilator-associated pneumonia bsed on total resource utilization. Annual Meeting of American Chest Physicians, Octrober 25-30, 2008, Philadelphia, PA.

Posters and Presentations

• Atkinson MA, Davidson N, Jones C. Effectively translate and communicate clinical outcomes and economic data to marketers and decision makers. The Aequitas Group. CBI presentation. December 5, 2007.
• Firth N, Davis L, Murry K, et al. Outsourcing industry medical information services. Drug Information Journal 2000;34:1105–1113.
• Hartzman D. CI pros vs. info pros—what's the difference. Webinar for Southern California Chapter, Special Libraries Association, 2006.
• Hartzman D. Competitive intelligence for information professionals, University of California, Los Angeles, August 2008.
• Jones C. Maximizing value through innovation. The Aequitas Group, CBI presentation, December 5, 2007.
• Marangos PJ, Papatheofanis FJ. The impact of myocardial perfusion imaging for detection of coronary artery disease on the health outcomes of asymptomatic patients with type 2 diabetes. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Marangos PJ, Papatheofanis FJ. Improvement in sensory pain rating after palliative radionuclide therapy in patients with advanced prostate cancer. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Marangos PJ, Papatheofanis FJ. A Markov model to assess the cost-effectiveness of a continuous glucose monitoring system with trending and rate information when used to predict and prevent hypo- and hyperglycemia in patients with type 1 diabetes. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Marangos PJ, Seybold P, Papatheofanis FJ. The cost-effectiveness of extracorporeal shock wave therapy for the treatment of chronic plantar fasciitis. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Marangos PJ, Seybold P, Papatheofanis FJ. Early health technology assessment: continuous glucose monitoring for the maintenance of glycemic control in insulin-requiring type 1 diabetes. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• O’Brien JA, Lahue BJ, Davidson D, Wilson DA, Caro JJ. Clostridium difficile-associated diarrhea (CDAD): initial hospital stay and readmission patterns during 24 month follow-up period. Poster, Society for Health Care Epidemiology of America annual meeting, 2006.
• Papatheofanis FJ. Early Detection of CVD by myocardial perfusion imaging in asymptomatic patients with diabetes. ISPOR 10th Annual International Meeting, May 15-18, 2005, Washington, DC.
• Papatheofanis FJ. Organization of a technology assessment institute for the United States. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Papatheofanis FJ, Marangos PJ. Cost-effectiveness of detection of CAD by myocardial perfusion imaging in asymptomatic patients with diabetes. ISPOR 10th Annual International Meeting, May 15-18, 2005, Washington, DC.
• Papatheofanis FJ, McKenzie RS, Mody S, Piech CT. Clinical and economic considerations of erythropoietic agent usage in predialysis chronic kidney disease patients. Kidney Disease Economics Conference, February 4-6 ,2005, Phoenix, AZ.
• Seybold P, Marangos PJ, Papatheofanis FJ. Health technology assessment: extracorporeal shock wave therapy (ESWT) for the treatment of chronic plantar fasciitis. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Sullivan N. Assessing the net health outcomes of a 4d electromagnetic tumor tracking system during radiotherapy for clinically localized prostate cancer: a health technology assessment of the Calypso® 4d localization system with Beacon® transponders. ISPOR 12th Annual International Meeting, May 19-23, 2007, Arlington, VA.
• Sullivan N. A Markov model evaluating the cost-utility of a 4d real-time electromagnetic tracking system (Calypso® 4d localization system with Beacon transponders) in the localization of prostate tumors during radiotherapy. ISPOR 12th Annual International Meeting,, May 19-23, 2007, Arlington, VA.
• Sullivan N. Cost-of-illness: economic evaluation of palliative 153 sm-lexidronam radionuclide treatment in patients with bone pain secondary to metastatic prostate cancer. ISPOR 12th Annual International Meeting, May 19-23, 2008,Arlington, VA.
• Sullivan N. HTA: how new technologies are assessed around the world. The Aequitas Group, San Diego, CA.
• Williams EN, Papatheofanis FJ. Calypso 4D localization system with Beacon transponders for continuous tumor localization and tracking during radiation therapy for clinically localized prostate cancer: an early health technology assessment. Poster, ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Williams E, Papatheofanis FJ. 4d localization system with transponders for continuous target localization for set-up and tracking during radiation therapy: early health technology assessment. ISPOR 11th Annual International Meeting, May 24-26, 2006, Philadelphia, PA.
• Wilson D. EBM and value: goal and constraint. The Aequitas Group, CBI presentation, December 5, 2007.
• Firth N. Rehearsing the future—scenario planning. Society of Insurance Research Meeting, March 29-April 1, 2009, Las Vegas, NV.

Manuscripts

• Drummond M, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care 2007; 23:1-7.
• Fang EN, Law S, Walt JG, Chiang TH, Williams EN. The prevalence of glaucomatous risk factors in patients from a managed-care setting: a pilot evaluation. American Journal of Managed Care 2008;14 (Suppl 1):S28-S36.
• Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PA, Thal K. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Archives of Neurology 2008;65:1031-1038.
• Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2007;68:1588-1595.
• Hatton RC, Gonzalez-Rothi R, Smith WD, et al. The use of virtual expert panels: formulary decision making in the twenty-first century. Formulary 2005;40:78-85.
• Huybrechts KF, Caro JJ, Wilson DA, O’Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value in Health 2005;8:549-561.
• May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW. Potential outcome measures and trial design issues for multiple system atrophy. Movement Disorders 2007;22:2371-2377.
• McGahan MC, Ramos GA, Landry C, Wolfson T, Sowell BB, D'Agostini D, Patino C, Nelson TR, Pretorius DH. Multislice display of the fetal face using 3-dimensional ultrasonography. Journal of Ultrasound Medicine 2008;27:1573-1581.
• Papatheofanis FJ. Comparative costs of treatment with epoetin alfa and darbepoetin alfa for anemia in the oncology and nephrology settings. Expert Review of Pharmacoeconomics and Outcomes Research 2007;7:59-73.
• Papatheofanis F, Bookhart BK, Muser E, Piech CT. Comparison of worker productivity and resource utilization between employees with anemia of pre-dialysis chronic kidney disease, healthy employees, and those with chronic obstructive pulmonary disease or rheumatoid arthritis. Journal of Health and Productivity 2008;3.
• Papatheofanis F, Bookhart BK, Muser E, Piech CT. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease. Journal of Occupational and Environmental Medicine 2008;50:584-589.
• Papatheofanis F, Najib M. Bone marrow recovery following use of systemic 153Sm-lexidronam and 89Sr-chloride for bone pain palliation after myelosuppressive therapy. International Journal of Radiation Biology, in press.
• Papatheofanis FJ, Smith C, Najib M. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer. American Journal of Therapeutics 2009;16:127-132.
• Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. American Journal of Therapeutics 2007;14:322-327.
• Papatheofanis FJ. Williams E, Chang SD. Cost-utility analysis of the cyberknife system for metastatic spinal tumors. Neurosurgery 2009;64(2 Suppl):A73-A83.
• Smith WD. Corticosteroids: an important cause of hyperglycemia. American Journal of Health-System Pharmacy 2005;62:1979.
• Smith WD, Hatton RC, Fann AL, Baz MA, Kaplan B. Drug interaction alerts for transplant medications: the prescribers’ perspective. Annals of Pharmacotherapy 2005;29:45-50.
• Smith WD, Winterstein AG, Johns TE, et al. Causes of hyperglycemia and hypoglycemia in adult in patients. American Journal of Health-System Pharmacy 2005;62:714-719.